Brokerages Set COMPASS Pathways plc (NASDAQ:CMPS) Target Price at $18.83

Shares of COMPASS Pathways plc (NASDAQ:CMPS - Get Free Report) have received an average recommendation of "Buy" from the six brokerages that are covering the firm, Marketbeat reports. Six analysts have rated the stock with a buy rating. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $18.83.

Several equities research analysts have recently weighed in on the company. Cantor Fitzgerald reissued an "overweight" rating and set a $12.00 target price on shares of COMPASS Pathways in a research report on Tuesday, May 27th. Stifel Nicolaus started coverage on COMPASS Pathways in a report on Thursday, February 27th. They issued a "buy" rating and a $11.00 target price on the stock. HC Wainwright restated a "buy" rating and set a $45.00 target price on shares of COMPASS Pathways in a research report on Monday, May 12th. Finally, Canaccord Genuity Group cut their price target on COMPASS Pathways from $23.00 to $15.00 and set a "buy" rating for the company in a report on Friday, February 28th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CMPS. Virtus ETF Advisers LLC increased its stake in shares of COMPASS Pathways by 21.4% in the fourth quarter. Virtus ETF Advisers LLC now owns 16,121 shares of the company's stock worth $61,000 after buying an additional 2,840 shares during the last quarter. Conservest Capital Advisors Inc. boosted its position in shares of COMPASS Pathways by 28.9% in the 4th quarter. Conservest Capital Advisors Inc. now owns 13,363 shares of the company's stock valued at $51,000 after purchasing an additional 3,000 shares during the period. Flagship Harbor Advisors LLC grew its stake in COMPASS Pathways by 27.7% during the 1st quarter. Flagship Harbor Advisors LLC now owns 14,446 shares of the company's stock valued at $41,000 after acquiring an additional 3,134 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of COMPASS Pathways by 93.6% in the 1st quarter. GAMMA Investing LLC now owns 10,349 shares of the company's stock valued at $30,000 after buying an additional 5,003 shares in the last quarter. Finally, Kennedy Capital Management LLC raised its stake in shares of COMPASS Pathways by 22.8% in the 4th quarter. Kennedy Capital Management LLC now owns 33,976 shares of the company's stock valued at $128,000 after acquiring an additional 6,297 shares in the last quarter. Institutional investors and hedge funds own 46.19% of the company's stock.

COMPASS Pathways Price Performance

NASDAQ CMPS traded down $0.13 during trading hours on Friday, hitting $4.39. 1,371,074 shares of the company's stock traded hands, compared to its average volume of 897,337. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.91 and a quick ratio of 8.91. COMPASS Pathways has a 52-week low of $2.49 and a 52-week high of $8.54. The firm's 50-day moving average is $3.87 and its 200-day moving average is $3.89. The company has a market capitalization of $410.74 million, a PE ratio of -2.00 and a beta of 2.25.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.44) EPS for the quarter, topping analysts' consensus estimates of ($0.47) by $0.03. Equities analysts forecast that COMPASS Pathways will post -2.33 EPS for the current fiscal year.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.